secwatch.observer — SEC 8-K summary
======================================

Issuer:     C4 Therapeutics, Inc. (CCCC)
CIK:        0001662579
Form:       8-K
Filed at:   2024-10-11T23:59:59+00:00
Accession:  0001628280-24-042728
Event type: other_material
Sentiment:  positive
Materiality: 0.25
Item codes: 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

C4 Therapeutics board requires shareholder approval for stock option repricing
------------------------------------------------------------------------------

- Board approved Amendment No. 1 to the 2020 Stock Option and Incentive Plan on Oct 7, 2024.
- Amendment requires stockholder approval for any reduction in exercise price or repricing of stock options or SARs.
- Previous administrator authority to reprice without stockholder approval is removed.
- Amendment is effective immediately and does not require stockholder approval.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1662579/000162828024042728/0001628280-24-042728-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1662579/000162828024042728/cccc-20241011.htm
  HTML page:      https://secwatch.observer/filing/0001628280-24-042728

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer